4
Changes in Ownership
Avalo Therapeutics, Inc. Filed Acc 0001918845-26-000008
Chief Medical Officer sold 3,970 shares at $18.01 ($71,508)
- Chief Medical Officer acquired 3,970 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Doyle Mittie · Chief Medical Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-04-06 | Exercise or conversion : show line 1 in the form 10b5-1 | +3,970 | $12.65 | $50,221 | 7,592 | D |
| 2026-04-06 | Sale : show line 2 in the form 10b5-1 | −3,970 | $18.01 | $71,508 | 3,622 | D |
| Open-market sales · 3,970 sh · avg $18.01 · $71,508 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-04-06 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (Right to Buy) | −3,970 | 210,530 | D |
Loading xslF345X06/form4-04082026_080437.xml…